Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06023654
Other study ID # 1926A
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 15, 2023
Est. completion date June 1, 2024

Study information

Verified date September 2023
Source University of Dublin, Trinity College
Contact Craig Gouldthorpe
Phone +35314986235
Email gouldthc@tcd.ie
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Circadian rest-Activity Rhythm disorders (CARDs) are common in patients with cancer, particularly in advanced disease. CARDs are associated with increased symptoms, poorer quality of life, poorer response to anticancer treatments and shorter survival. The goal of this observational study is to see how common CARDs are in patients with advanced cancer and to characterise their rest and activity patterns in more detail. A recent study has outlined a standard way to assess and diagnose a CARD. This study aims to assess patients with advanced cancer for a CARD using a novel screening tool against this newly formed diagnostic criteria. Potentially modifiable risk factors will be considered along with associations between CARDs and symptoms, sleep preferences, sleep quality, daytime sleepiness, quality of life measures and predictors of survival.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult (18 years of age or older) - Locally advanced or metastatic cancer - Outpatient - Ambulatory - Prognosis of 3 months or more Exclusion Criteria: - Inpatient - Shiftworker - Recent long-haul travel - Cognitive impairment impacting on ability to complete questionnaires

Study Design


Locations

Country Name City State
Ireland Our Lady's Hospice & Care Services Dublin
Ireland St James's Hospital Dublin

Sponsors (2)

Lead Sponsor Collaborator
University of Dublin, Trinity College Our Lady's Hospice and Care Services

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure preliminary concurrent validity of a novel screening tool to identify Circadian rest-Activity Rhythm Disorders in patients with advanced cancer against diagnostic criteria Assessing the sensitivity and specificity of the screening tool Time 1 (baseline), Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To measure test-retest reliability of a novel screening tool to identify Circadian rest-Activity Rhythm Disorders in patients with advanced cancer Assessing the correlation between scores from the screening tool at two time points Time 1 (baseline), Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To measure acceptability and ease of use of a novel screening tool to identify Circadian rest-Activity Rhythm Disorders in patients with advanced cancer Patient ease of use, understandability, acceptability and time to complete. Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To measure acceptability and ease of use of a novel sleep and activity diary in patients with advanced cancer Patient ease of use, understandability, and acceptability Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To identify the incidence of Circadian rest-activity Rhythm Disorders in patients with advanced cancer Incidence of Circadian rest-Activity Rhythm Disorders as identified by diagnostic criteria Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess rest and physical activity patterns in patients with advanced cancer Combined assessment using wrist and thigh accelerometry alongside a sleep and activity diary Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess the relationship between demographic details and the risk of developing a Circadian rest-Activity Rhythms in patients with cancer Baseline demographic details collected using a questionnaire Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess the relationship between past medical history and the risk of developing a Circadian rest-Activity Rhythms in patients with cancer Past medical history collected using a questionnaire Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess the relationship between current medication use and the risk of developing a Circadian rest-Activity Rhythms in patients with cancer Current medication use collected using a questionnaire Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess the relationship between chronotype and the risk of develop a Circadian rest-Activity Rhythms in patients with cancer Chronotype assessed using the Morningness-Eveningness Questionnaire (MEQ) Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess the relationship between occupation and the risk of developing a Circadian rest-Activity Rhythms in patients with cancer Occupation provided by participant using a questionnaire Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess the relationship between cigarette use and the risk of developing a Circadian rest-Activity Rhythms in patients with cancer Number and timing of last cigarette smoked each day assessed using a patient diary During 72 hours period of monitoring
Secondary To assess the relationship between alcohol consumption and the risk of developing a Circadian rest-Activity Rhythms in patients with cancer Number and timing of alcoholic beverages consumed each day assessed using a patient diary During 72 hours period of monitoring
Secondary To assess the relationship between caffeine consumption and the risk of developing a Circadian rest-Activity Rhythms in patients with cancer Number and timing of last of caffeinated drink consumed each day assessed using a patient diary During 72 hours period of monitoring
Secondary To assess associations between Circadian rest-activity Rhythm Disorders in patients with advanced cancer with symptoms Symptoms measured using the Memorial Symptom Assessment Scale - Short Form (MSAS-SF) Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess associations between Circadian rest-activity Rhythm Disorders in patients with advanced cancer and prognosis Prognosis measured using the Prognosis in Palliative Care tool (PiPS-B) Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess associations between Circadian rest-activity Rhythm Disorders in patients with advanced cancer with quality of life Quality of Life measured using the EORTC Quality of Life Questionnaire (EORTC-QLQ-C30) Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess associations between Circadian rest-activity Rhythm Disorders in patients with advanced cancer with sleep quality Sleep quality measured using the brief Pittsburgh Sleep Quality Instrument (bPSQI) Time 2 (after 72 consecutive hours of accelerometry monitoring)
Secondary To assess associations between Circadian rest-activity Rhythm Disorders in patients with advanced cancer with daytime sleepiness Daytime sleepiness assess using the Epworth Sleepiness Scale Time 2 (after 72 consecutive hours of accelerometry monitoring)
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases